コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 cked evidence of right-sided endocarditis or thrombophlebitis.
2 warfarin in the prevention and treatment of thrombophlebitis.
3 had varicose veins and developed superficial thrombophlebitis.
4 lar shunt, or arteriovenous fistula to avoid thrombophlebitis.
5 monary embolism, and another had superficial thrombophlebitis.
8 osis, one ocular thrombosis, one superficial thrombophlebitis, and one death (after cessation of the
9 tion, infection, deep vein thrombosis [DVT], thrombophlebitis, and venous stenosis) were assessed.
10 t treatments for lower extremity superficial thrombophlebitis are associated with lower rates of veno
11 spontaneous, recurrent superficial migratory thrombophlebitis associated with occult cancers, and thi
12 ary resuscitation, deep venous thrombosis or thrombophlebitis, coma lasting >24 hours, acute renal fa
13 .50); silicone catheters increased phlebitis/thrombophlebitis compared to nonsilicone (one RCT, RR 2.
14 Trousseau noted that unexpected or migratory thrombophlebitis could be a forewarning of an occult vis
15 eloped vascular events ranging from repeated thrombophlebitis, deep vein thrombosis, pulmonary emboli
16 eloped vascular events ranging from repeated thrombophlebitis, deep vein thrombosis, pulmonary emboli
17 occurrence of venous thrombosis (superficial thrombophlebitis) during the first 3 months of follow-up
18 e associated with lower rates of superficial thrombophlebitis extension or recurrence, but data regar
19 RCT, RR 0.47, 95%CI 0.31-0.72) and phlebitis/thrombophlebitis in adults (one RCT, RR 0.35, 95%CI 0.22
20 -guided catheter insertion reduced phlebitis/thrombophlebitis in adults compared to non-ultrasound-gu
21 es potentially resulted in a lower phlebitis/thrombophlebitis incidence (10 RCTs; RR, 0.74, 95% credi
23 llulitis (six)], vascular system [18; septic thrombophlebitis (nine), infection of implantable cathet
28 on, tip migration, infiltration, superficial thrombophlebitis, or exit site concerns) and device fail
29 egard to infusion-related AEs such as fever, thrombophlebitis, or fluid overload between the groups.
30 zed clinically in the context of superficial thrombophlebitis (thrombosis and inflammation of superfi
32 c stroke, sub/epidural hematoma, or cerebral thrombophlebitis was identified as the primary cause of
34 gh more frequent infusion site pain/erythema/thrombophlebitis was seen with fosaprepitant relative to
35 .9) patients with MRDTI negative for DVT and thrombophlebitis, who were not treated with any anticoag